TABLE 1.
Clinical Characteristics of 18 Patients with Bloodstream Infections due to Daptomycin-Resistant Vancomycin-Resistant Enterococci (VRE) at Memorial Sloan-Kettering Cancer Center (2007—2009)
| Duration of prior exposure, days |
||||||||
|---|---|---|---|---|---|---|---|---|
| Year, patient no. |
Age, sex | Underlying cancer | DAP | VANC | Treatment | 30-day mortality |
Duration of bacteremia, days |
Isolate resistance profile |
| 2009 | ||||||||
| 1 | 71, F | Breast | 0 | 90 | None | Yes | 1 | DAP resistant only |
| 2 | 6, F | NB | 5 | 16 | DAP | No | 10 | Mixed with DAP susceptible |
| 3 | 55, M | AML | 0 | 134 | LZD | Yes | 1 | DAP resistant only |
| 4 | 80, F | Ovarian | 0 | 2 | LZD | Yes | 4 | Mixed with DAP susceptible |
| 5 | 58, F | CLL | 0 | 20 | LZD | No | 2 | DAP resistant only |
| 6 | 66, F | Lymphoma | 0 | 0 | LZD | No | 1 | DAP resistant only |
| 7 | 79, M | Lung | 0 | 0 | LZD | Yes | 1 | DAP resistant only |
| 8 | 57, F | ALL-DUCBT | 0 | 13 | DAP gent | Yes | 18 | LZD and DAP resistant |
| 9 | 32, M | ALL-DUCBT | 0 | 31 | DAP, LZD | No | 9 | Mixed with DAP susceptible |
| 10 | 68, M | AML-PBSCT | 0 | 37 | LZD | No | 7 | Mixed with DAP susceptible |
| 2008 | ||||||||
| 11 | 25, M | AML | 0 | 2 | LZD | Yes | 15 | Mixed with DAP susceptible |
| 12 | 61, F | MDS/AML | 0 | 47 | LZD | No | 1 | Mixed with DAP susceptible |
| 13 | 60, F | Lymphoma | 0 | 26 | LZD | No | 1 | DAP resistant only |
| 14 | 65, F | MDS/PBSCT | 0 | 15 | LZD | No | 3 | Mixed with DAP susceptible |
| 15 | 68, M | Lymphoma/PBSCT | 0 | 1 | LZD | No | 2 | Mixed with DAP susceptible |
| 16 | 26, M | ALL/PBSCT | 0 | 49 | LZD | No | 4 | Mixed with DAP susceptible |
| 2007 | ||||||||
| 17 | 64, M | AML | 17 | 39 | LZD | Yes | 5 | DAP resistant only |
| 18 | 72, M | AML | 0 | 19 | LZD | No | 1 | Mixed with DAP susceptible |
note. ALL, acute lymphocytic leukemia; AML, acute myelogenous leukemia; CLL, chronic lymphocytic leukemia; DAP, daptomycin; DUCBT, double umbilical cord blood transplant; gent, gentamicin; LZD, linezolid; MDS, myelodysplastic syndrome; NB, neuroblastoma; PBSCT, peripheral blood stem cell transplant; VANC, vancomycin.